SCHEMBL2677633

SCHEMBL2677633

NC(=O)c1cccc(F)c1C(=O)Nc1n[nH]c2c1CN(S(=O)(=O)c1cc(F)cc(F)c1)CC2

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.59
CCNA2 P20248 2/20 0.42
CDK2 P24941 2/20 0.42
CCNA1 P78396 2/20 0.42
AURKA O14965 1/20 0.42
EP300 Q09472 3/20 0.40
CREBBP Q92793 3/20 0.40
MET P08581 4/20 0.38
HMOX1 P09601 2/20 0.37
RBP4 P02753 1/20 0.36
RORC P51449 2/20 0.35
NR1I2 O75469 1/20 0.35
RORA P35398 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
RORB Q92753 1/20 0.35
NR1H4 Q96RI1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677636 0.90 IGF1R (0.61) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL2678341 0.90 IGF1R (0.63) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL2678537 0.89 IGF1R (0.47) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL1895246 0.85 IGF1R (0.58) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL1889296 0.84 IGF1R (0.59) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL1886628 0.84 IGF1R (0.63) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL2678097 0.84 IGF1R (0.43) IGF1RCCNA2CDK2CCNA1
SCHEMBL1888330 0.84 IGF1R (0.56) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL1888347 0.83 IGF1R (0.56) IGF1RCCNA2CDK2CCNA1AURKA
SCHEMBL1888100 0.83 IGF1R (0.58) IGF1RCCNA2CDK2CCNA1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885CCNA2 1202/4885CDK2 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.